Login to Your Account


Breast-case scenarios: Evomela OK'd, Spectrum goes wider with pipeline

By Randy Osborne
Staff Writer

Friday, March 11, 2016

After early approval last week by the FDA of Spectrum Pharmaceuticals Inc.'s multiple myeloma (MM) therapy Evomela (Captisol-enabled [CE] melphalan), investor eyes turned toward other assets, including the next candidate for market clearance: Eoquin (apaziquone) for non-muscle invasive bladder cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription